文献速递肿瘤 PET/CT放射性药物与辐射防护

二氯化[64Cu]铜的人体生物分布与辐射剂量学:健康志愿者的首次人体研究

Biodistribution and radiation dosimetry of [64Cu]copper dichloride: first-in-human study in healthy volunteers.
PubMed 文献 · EJNMMI Res · 2017-12-12

该研究在6名健康志愿者中静脉注射[64Cu]CuCl2(4.0 MBq/kg)后行全身PET扫描,评估生物分布与辐射剂量。最高摄取在肝脏,其次为下段和上段大肠壁及胰腺;尿排泄可忽略。肝脏为关键器官,男性平均吸收剂量310 ± 67 μGy/MBq、女性421 ± 56 μGy/MBq;全身有效剂量男性51.2 ± 3.0 μSv/MBq、女性61.8 ± 5.2 μSv/MBq。

要点

  • 健康志愿者中[64Cu]CuCl2最高摄取位于肝脏,其次为下段和上段大肠壁及胰腺,尿排泄可忽略。
  • 关键器官为肝脏,男性平均吸收剂量310 ± 67 μGy/MBq,女性421 ± 56 μGy/MBq。
  • 全身有效剂量男性51.2 ± 3.0 μSv/MBq,女性61.8 ± 5.2 μSv/MBq。

核心结论

  • 据作者所知,这是[64Cu]CuCl2在健康志愿者中生物分布与辐射剂量学的首次报告。
  • 测得的吸收剂量和有效剂量高于既往以前列腺癌患者生物分布数据估算的剂量,差异可能不仅源于癌症患者与健康志愿者生物分布不同,更可能源于分析技术和剂量计算假设的差异。

研究设计与样本

  • 研究纳入6名健康志愿者(3女3男,平均年龄 ± 标准差54.3 ± 8.6岁;平均体重 ± 标准差77.2 ± 12.4 kg)。
  • 静脉注射[64Cu]CuCl2(4.0 MBq/kg)后,于注射后5、30、60分钟采集连续三次全身发射扫描,并于注射后5、9、24小时追加扫描。
  • 使用无对比剂低剂量CT进行解剖定位和衰减校正,采用OLINDA/EXM软件以参考成人模型计算人体辐射剂量。

主要发现

  • 最高摄取位于肝脏,其次为下段和上段大肠壁及胰腺,按降序排列;尿排泄可忽略。
  • 关键器官为肝脏,男性平均吸收剂量310 ± 67 μGy/MBq,女性421 ± 56 μGy/MBq。
  • 全身有效剂量男性51.2 ± 3.0 μSv/MBq,女性61.8 ± 5.2 μSv/MBq。

局限性

  • 测得的吸收剂量和有效剂量高于既往以前列腺癌患者生物分布数据估算的剂量,差异可能不仅源于癌症患者与健康志愿者生物分布不同,更可能源于分析技术和剂量计算假设的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In recent years, Copper-64 (T1/2 = 12.7 h) in the chemical form of copper dichloride ([64Cu]CuCl2) has been identified as a potential agent for PET imaging and radionuclide therapy targeting the human copper transporter 1, which is overexpressed in a variety of cancer cells. Limited human biodistribution and radiation dosimetry data is available for this tracer. The aim of this research was to determine the biodistribution and estimate the radiation dosimetry of [64Cu]CuCl2, using whole-body (WB) PET scans in healthy volunteers. Six healthy volunteers were included in this study (3 women and 3 men, mean age ± SD, 54.3 ± 8.6 years; mean weight ± SD, 77.2 ± 12.4 kg). After intravenous injection of the tracer (4.0 MBq/kg), three consecutive WB emission scans were acquired at 5, 30, and 60 min after injection. Additional scans were acquired at 5, 9, and 24 h post-injection. Low-dose CT scan without contrast was used for anatomic localization and attenuation correction. OLINDA/EXM software was used to calculate human radiation doses using the reference adult model. RESULTS: The highest uptake was in the liver, followed by lower and upper large intestine walls, and pancreas, in descending order. Urinary excretion was negligible. The critical organ was liver with a mean absorbed dose of 310 ± 67 μGy/MBq for men and 421 ± 56 μGy/MBq for women, while the mean WB effective doses were 51.2 ± 3.0 and 61.8 ± 5.2 μSv/MBq for men and women, respectively. CONCLUSIONS: To the best of our knowledge, this is the first report on biodistribution and radiation dosimetry of [64Cu]CuCl2 in healthy volunteers. Measured absorbed doses and effective doses are higher than previously reported doses estimated with biodistribution data from patients with prostate cancer, a difference that could be explained not just due to altered biodistribution in cancer patients compared to healthy volunteers but most likely due to the differences in the analysis technique and assumptions in the dose calculation.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Avila-Rodriguez MA, Rios C, Carrasco-Hernandez J, et al. Biodistribution and radiation dosimetry of [64Cu]copper dichloride: first-in-human study in healthy volunteers. EJNMMI Res. 2017. PMID: 29234903. doi:10.1186/s13550-017-0346-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。